Press Releases

December 10, 2019
Navigen Announces FDA Clearance of its IND Application to Initiate First-in-Human Studies for CPT31, a Novel, D-peptide HIV Entry Inhibitor
February 14, 2019
Navigen Announces the Election of Two Biotechnology Industry Veterans to its Board of Directors
September 27, 2018
Navigen Receives NIH Grant to Develop D-peptide Inhibitors of TNF-α for Treatment of Inflammatory Bowel Disease
April 13, 2018
Navigen Announces That David Ho, M.D. Has Joined its HIV Scientific Advisory Board
November 20, 2017
BioUtah's Willem J. Kolff Lifetime Achievement Award Given to Dr. Hunter Jackson, Navigen Co-founder and Chairman
October 4, 2017
Navigen Receives NIH Grant to Develop D-peptide Inhibitors of SIRPα, an Important Target in Cancer Immunotherapy
September 18, 2017
Navigen Awarded $4.9MM to Advance its HIV Entry Inhibitor CPT31
July 26, 2017
Navigen Presents Promising Pre-Clinical Data on CPT31 at the 9th International AIDS Society Conference on HIV Science
April 25, 2017
Navigen Announces $1.7MM Phase II NIH SBIR Award to Support the Development of ARF6 Inhibitors for Treatment of Acute Lung Injury
October 20, 2016
Dr. Michael Kay Presents Recent Data on Navigen's HIV Entry Inhibitor, CPT31, at the 2016 HIVR4P meeting
August 24, 2016
Navigen Awarded $500,000 Grant to Support Depot Formulation of its HIV Drug Candidate